Pricing Log in Create free account

Lineage Cell Therapeutics, Inc. (LCTX) vs Q32 Bio Inc. (QTTB)

Lineage Cell Therapeutics, Inc. and Q32 Bio Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and Q32 Bio Inc. are of similar size ($276.8M and $258.0M). Lineage Cell Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Q32 Bio Inc. trades at 3.1×. Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −307.3%. Q32 Bio Inc. has the higher net margin (0.00% vs −246.6%) and the higher return on invested capital (0.00% vs −186.8%). Across the 17 metrics below, Q32 Bio Inc. leads on 16 and Lineage Cell Therapeutics, Inc. on 1.

Valuation

Metric LCTX QTTB Biotechnology median
P/E n/m 3.06 10.60
P/S 19.45 n/m 9.40
P/B 4.26 1.78 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 15.57 (13.54) 9.02
Earnings yield (14.10%) 32.65% (32.88%)
Free cash flow yield (9.58%) (6.86%) (23.13%)

Profitability

Metric LCTX QTTB Biotechnology median
Gross margin 99.46% 100.00% 68.51%
Operating margin (205.23%) 0.00% 0.00%
Net margin (246.58%) 0.00% 0.00%
Free cash flow margin (186.43%) 0.00% 0.00%
Return on equity (60.35%) 72.14% (51.96%)
Return on assets (32.75%) 37.13% (46.06%)
Return on invested capital (186.79%) 0.00% 0.00%

Growth

Metric LCTX QTTB Biotechnology median
Revenue growth (TTM) 19.87% (307.33%) 6.76%
EPS growth (last fiscal year) (211.11%) 136.78% 29.88%
Revenue growth, 5-year CAGR 51.46% 100.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LCTX QTTB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.61 20.30 4.97
Net debt to EBITDA 2.64 (2.21) 1.01

Dividend

Metric LCTX QTTB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LCTX QTTB Biotechnology median
Market cap 257.97m 276.80m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack